BOCA RATON, Fla., Sept. 8 /PRNewswire/ -- NovaVision today announced that the company has been selected to present at the prestigious AdvaMed 2008: The MedTech Conference (http://www.advamed2008.com), on Monday, September 22, 2008 in Washington, DC.
During the presentation, which falls in the "Next Generation" category, Mr. Rudy Mazzocchi, the newly appointed chief executive officer of NovaVision, will address the increasing use of Vision Restoration Therapy (VRT) among U.S. and global healthcare providers. VRT is a non-invasive medical device cleared by the United States Food & Drug Administration to help restore vision to the millions of underserved people living with impaired sight caused by a stroke or traumatic brain injury (TBI).
Using the science of neuroplasticity -- the brain's ability to rewire itself -- VRT is an in-home personalized restoration therapy that uses light-based stimuli to gradually activate adjacent neurons in the brain responsible for vision. Each patient receives a program that is entirely customized to their own unique visual field deficits. Every month, the patient receives an advanced program to correlate to individual progress. Clinical trials show that nearly 70-80% of all patients show improved vision following therapy, regardless of how long ago their stroke or TBI occurred.
About NovaVision, Inc.
NovaVision, Inc., headquartered in Boca Raton, Fla., develops and
provides scientifically-based, innovative medical devices and comprehensive
solutions to restore the vision of patients with neurological visual
impairments. FDA-cleared in 2003, NovaVision's Vision Restoration Therapy
devices work by enhancing neuroplasticity -- the brain's ability to adapt
and form new connections to compensate for injury. NovaVision's diagnostic
program maps areas where vision may be improved, and the therapy program
targets and stimulates regions within the brain's
|SOURCE NovaVision, Inc.|
Copyright©2008 PR Newswire.
All rights reserved